Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Raad S, Hanna N, Jalal S, Bendaly E, Zhang C, Nuguru S, et al. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Use for Subclassification and Genotyping of Lung Non-Small-Cell Carcinoma. South Med J. 2018;111(8):484-488.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, et al. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precis Oncol. 2018;2018.

Jacobs SE, Zhong E, Hartono C, Satlin MJ, Magro CM, Jenkins SG, et al. The Brief Case: Disseminated Mycobacterium haemophilum Infection in a Kidney Transplant Recipient. J Clin Microbiol. 2018;56(1).

Goyal A, Zhang G, Yang B. Differential expression patterns of GATA3 in usual and differentiated types of vulvar intraepithelial neoplasia: potential diagnostic implications. Mod Pathol. 2018;31(7):1131-1140.

Ko H-, Berk M, Chung Y-, Willard B, Bareja R, Rubin M, et al. Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate Cancer. Cell Rep. 2018;22(3):809-819.

Morrone KA, Pecker LH, Rand J, Davila J, Oyeku S, Little JA, et al. Association of silent infarcts in sickle cell anemia with decreased annexin A5 resistance. Blood Cells Mol Dis. 2018;69:53-56.

Alves CP, Dey-Guha I, Kabraji S, Yeh AC, Talele NP, Solé X, et al. AKT1 Quiescent Cancer Cells Promote Solid Tumor Growth. Mol Cancer Ther. 2018;17(1):254-263.

Bellazzo A, Di Minin G, Valentino E, Sicari D, Torre D, Marchionni L, et al. Cell-autonomous and cell non-autonomous downregulation of tumor suppressor DAB2IP by microRNA-149-3p promotes aggressiveness of cancer cells. Cell Death Differ. 2018;25(7):1224-1238.

Arenas MA, Whitsett TG, Aronova A, Henderson SA, LoBello J, Habra MA, et al. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma. Ann Surg Oncol. 2018;25(3):801-807.

Cheng S, Inghirami G, Cheng S, Tam W. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. J Hematol Oncol. 2018;11(1):105.